Patient Selection
AIRFLOW-3 is the first major interventional trial targeting reduction of exacerbations in COPD patients with a high symptom burden.
Contact us to get more information on patient selection and referring patients.
Up to 400 Patients
Key Patient Screening Criteria
Diagnosed COPD FEV1 25-80% post-bronchodilator
40+ years old, BMI 18-35
High Symptom Burden
COPD Exacerbations: 2+ Moderate OR 1+ Severe in Past Year
Ex-Smoker 2+ Months
Dual or Triple Therapy
Current Flu Vaccine
Resting SpO2 ≥ 89% on Room Air
No Uncontrolled Gastric Symptoms
Looking for a complete list of inclusion and exclusion criteria?
Patient Selection
AIRFLOW-3 Trial Highlights
Trial Elements
1:1 Randomized • Double Blind • Sham-Controlled • FDA Pivotal Trial
Multicenter Trial
US and Europe
Patient Count
Up to 400 Patients
Primary Endpoint:
Comparison of the probability of subjects having a moderate or severe exacerbation between the treatment arm and the sham control arm at one year.
Do you have a patient that may be a good fit?
Here’s what patients enrolled in the AIRFLOW-3 Clinical Trial can expect:
- Evaluations of their COPD at a designated study location.
- Initial hospital screening tests and procedures.
- Monthly phone calls and two office visits during the first year after the procedure.
- A 12-month visit, after which the patient is informed whether or not they received the procedure or were part of the Sham group. Patients in the sham group are given the option of receiving the procedure at no cost.
- Ongoing evaluations of COPD symptoms and results over a 5-year period.
Get More Information on Referring Patients.
